Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis

Overview

Lung adenocarcinomas (LUADs) from Asian ancestry are reported to have different genomic architectures compared with LUADs from Caucasian ancestry. However, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. In this study, the investigators will identify Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital. Then, Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. Finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. This study will elucidate important ancestry differences between Asian and Caucasian lung adenocarcinoma patients.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 2021

Arms, Groups and Cohorts

  • Asian lung adenocarcinoma
    • Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People’s Hospital
  • Caucasian lung adenocarcinoma
    • Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations

Clinical Trial Outcome Measures

Primary Measures

  • Oncoprint of somatic mutations
    • Time Frame: July 2021
    • Association between genomic features and race
  • Copy number variations (CNVs)
    • Time Frame: July 2021
    • CNVs analysis by race
  • Mutational signatures
    • Time Frame: August 2021
    • Analysis of mutational signatures by race
  • Oncogenic pathways
    • Time Frame: September 2021
    • Analysis of oncogenic pathways by race
  • Therapeutic actionability
    • Time Frame: October 2021
    • Analysis of actionable alterations by race

Participating in This Clinical Trial

Inclusion Criteria

  • Primary lung adenocarcinoma – Broad-panel next-generation sequencing – Asian Exclusion Criteria:

  • Inadequate clinicopathological information – Low-quality next-generation sequencing

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jun Wang
  • Collaborator
    • Berry Genomics Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Jun Wang, Professor – Peking University People’s Hospital
  • Overall Contact(s)
    • Jian Zhou, MD, 010-88326650, zhoujianmd@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.